<DOC>
	<DOCNO>NCT00166426</DOCNO>
	<brief_summary>This study patient prostate cancer treat surgical removal prostate consider risk prostate cancer recurrence receive Exisulind 250 mg twice day placebo twice day two year .</brief_summary>
	<brief_title>Exisulind Versus Placebo After Surgical Removal Prostate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>Males 18 year age old prostate cancer treat primarily radical prostatectomy randomize within 45 day surgery may eligible enrollment protocol . Participants hormonal therapy , cryotherapy , thermotherapy , radiotherapy prior enter study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>